Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

Journal of Clinical Medicine Research
Takashi IizukaIkuro Matsuba

Abstract

Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipragliflozin in the real-world clinical setting, with a focus on the changes of body composition up to 3 months of treatment. This was a prospective multicenter interventional trial. We investigated changes of the blood pressure, body composition, blood glucose, hemoglobin A1c (HbA1c), ketone bodies, lipids, and insulin after treatment with ipragliflozin (50 - 100 mg/day) for 12 weeks in Japanese patients with T2DM who showed poor glycemic control despite receiving diet and exercise therapy with or without oral antidiabetic drugs for more than 12 weeks. Two hundred and fifty-seven subjects were included in the efficacy analysis up to 12 weeks of treatment and 301 subjects were included in the safety analysis. From baseline to 12 weeks, HbA1c showed a change of -0.68% (95% confidence interval (CI): -0.83, -0.53) and fasting blood glucose showed a change of -23.9 mg/dL (95% CI: -30.5, -17.2), with both parameters displaying a significant reduction (P < 0.001). The difference of body weight from baseline wa...Continue Reading

Citations

Jul 20, 2016·Oxidative Medicine and Cellular Longevity·José Pedraza-ChaverriAlexandra Scholze
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Hiroyuki ItoMariko Abe
Dec 27, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshio SumidaUNKNOWN Japan Study Group of NAFLD (JSG-NAFLD)
Jun 8, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahiro Okumura, Toyoaki Murohara
Nov 3, 2016·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshiyuki TakasuKaori Hamada
Jun 19, 2018·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Ahmed ElgebalyNoha Nasreldin

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.